These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27594356)

  • 41. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
    Butler J; Giamouzis G; Giannakoulas G
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
    Palmerini E; Söderberg S; Mondillo S; Favilli R; Lunghetti S
    Acute Card Care; 2015 Mar; 17(1):14-9. PubMed ID: 25806830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dear levosimendan, the right ventricle will thank you!
    Westphal M; Morelli A; Van Aken H
    Crit Care Med; 2007 Mar; 35(3):952-3. PubMed ID: 17421086
    [No Abstract]   [Full Text] [Related]  

  • 44. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Site dependent bioavailability and metabolism of levosimendan in dogs.
    Antila S; Huuskonen H; Nevalainen T; Kanerva H; Vanninen P; Lehtonen L
    Eur J Pharm Sci; 1999 Oct; 9(1):85-91. PubMed ID: 10494001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myocardial efficiency during levosimendan infusion in congestive heart failure.
    Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
    Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH
    Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A; Erhardt L
    Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    J Clin Pharmacol; 2004 Oct; 44(10):1143-50. PubMed ID: 15342615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levosimendan in acute and chronic right ventricle failure.
    Yontar OC; Yilmaz MB; Yalta K
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):118-9. PubMed ID: 19961440
    [No Abstract]   [Full Text] [Related]  

  • 55. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
    J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
    Jia Z; Guo M; Zhang YQ; Liang HQ; Zhang LY; Song Y
    Cardiology; 2014; 128(2):195-201. PubMed ID: 24751462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E; Moosbauer W; Pinter M; Mair R; Tulzer G
    Pediatr Crit Care Med; 2007 Jan; 8(1):61-3. PubMed ID: 17149153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
    Kolseth SM; Wahba A; Kirkeby-Garstad I; Aro S; Nordgaard H; Høydal M; Rognmo Ø; Nordhaug D
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):1377-83. PubMed ID: 22219475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.